MediBeacon Transdermal GFR System
Medibeacon, Inc. · Decision date Oct 2, 2026
What did the FDA approve?
The FDA record P230019/S005, dated 2026-10-02, documents an approval of a Special (Immediate Track) supplement to the MediBeacon Transdermal GFR System PMA, filed by Medibeacon, Inc. under product code SDK. The listed reason is a process change affecting a manufacturer, sterilizer, packager or supplier. Because the identifier shares the P230019 base number, the filing amends that existing PMA rather than covering a new device submission.
The stated change covers an additional package integrity test method for routine testing of Lumitrace and additional verification steps in the monitor manufacturing process. The record does not describe the test method, the verification steps, their acceptance criteria or any supporting data. The approval reflects the agency's acceptance of the described process changes; it is not reported evidence of safety, clinical effectiveness or a new indication for the device category, a transdermal test for assessment of glomerular filtration rate.
FDA approval order statement
approval for an additional package integrity test method for routine testing of Lumitrace, and additional verification steps in the monitor manufacturing process.
- Regulatory pathway
- PMA supplement
- Supplement type
- Special (Immediate Track)
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Oct 2, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P230019/S005
- Regulatory pathway
- PMA supplement
- Applicant
- Medibeacon, Inc.
- Product code
- SDK
- Decision code
- APPR
- Decision date
- Oct 2, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Transdermal test for Assessment of Glomerular Filtration Rate.
- Applicant
- Medibeacon, Inc.
- Product code
- SDK
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P230019. Subsequent supplements may change the device or its indications.
FDA decision timeline
P230019 · Original PMA
MediBeacon Transdermal GFR Measurement System (TGFR)
P230019/S005 received
Application receipt date recorded by FDA.
P230019/S005 · FDA decision
Special (Immediate Track)
Timeline entries are records held by MedtechLedger for P230019. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230019
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medibeacon, Inc. | PMA approval | Jan 17, 2025 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medibeacon, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 425 N. New Ballas Rd., Suite 100, St. Louis, MO, 63141
Sources and methodology
- Original FDA record: P230019/S005
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records